AIMMUNE THERAPEUTICS INC's ticker is AIMT and the CUSIP is 00900T107. A total of 153 filers reported holding AIMMUNE THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 0.71 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $99,000 | +106.2% | 2,879 | 0.0% | 0.00% | – |
| Q2 2020 | $48,000 | +14.3% | 2,879 | 0.0% | 0.00% | – |
| Q1 2020 | $42,000 | -56.2% | 2,879 | 0.0% | 0.00% | – |
| Q4 2019 | $96,000 | -15.0% | 2,879 | -46.9% | 0.00% | – |
| Q2 2019 | $113,000 | -6.6% | 5,426 | 0.0% | 0.00% | – |
| Q1 2019 | $121,000 | +59.2% | 5,426 | +63.7% | 0.00% | – |
| Q4 2018 | $76,000 | -16.5% | 3,315 | 0.0% | 0.00% | – |
| Q3 2018 | $91,000 | +2.2% | 3,315 | 0.0% | 0.00% | – |
| Q2 2018 | $89,000 | -16.0% | 3,315 | 0.0% | 0.00% | – |
| Q1 2018 | $106,000 | -15.2% | 3,315 | 0.0% | 0.00% | – |
| Q4 2017 | $125,000 | +54.3% | 3,315 | 0.0% | 0.00% | – |
| Q3 2017 | $81,000 | +19.1% | 3,315 | 0.0% | 0.00% | – |
| Q2 2017 | $68,000 | -5.6% | 3,315 | 0.0% | 0.00% | – |
| Q1 2017 | $72,000 | +5.9% | 3,315 | 0.0% | 0.00% | – |
| Q4 2016 | $68,000 | – | 3,315 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management II, LLC | 3,300,797 | $90,046,000 | 33.32% |
| Aisling Capital LLC | 1,990,000 | $54,287,000 | 11.73% |
| Foresite Capital Management III, LLC | 801,240 | $21,858,000 | 4.82% |
| PACIFIC VIEW ASSET MANAGEMENT, LLC | 189,857 | $5,181,000 | 4.12% |
| AlpInvest Partners B.V. | 38,943 | $1,062,000 | 2.27% |
| Eventide Asset Management | 1,739,000 | $47,440,000 | 1.74% |
| Palo Alto Investors LP | 1,381,759 | $37,694,000 | 1.52% |
| Sofinnova Investments, Inc. | 222,295 | $6,064,000 | 0.54% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 553,000 | $15,086,000 | 0.54% |
| EMERALD ADVISERS, LLC | 486,666 | $13,276,000 | 0.49% |